Statute Details
- Title: Human Organ Transplant (Specified Products) Notification 1987
- Act Code: HOTA1987-N1
- Legislative Type: Subsidiary legislation (Notification)
- Authorising Act: Human Organ Transplant Act 1987
- Key Provision Cross-Reference: Exemption from section 13(1) of the Human Organ Transplant Act 1987
- Status: Current version as at 27 Mar 2026
- Current Revised Edition: 2025 RevEd (2 June 2025)
- Original Citation: [16 July 1987]
- Most Recent Amendment Noted in Extract: Amended by S 694/2022 (effective 31 Dec 2021 in the timeline)
What Is This Legislation About?
The Human Organ Transplant (Specified Products) Notification 1987 is a Singapore subsidiary instrument made under the Human Organ Transplant Act 1987. In practical terms, it creates a targeted exemption: it identifies certain categories of human-derived products that are not subject to the restrictions in section 13(1) of the Human Organ Transplant Act 1987.
Although the Human Organ Transplant Act is commonly associated with organ transplantation, the Act also regulates related matters involving human tissue and human-derived materials. Section 13(1) is therefore part of a broader regulatory framework. This Notification narrows the scope of that framework by carving out specific products—such as certain blood products, hormones, vaccines, toxoids, and diagnostic agents derived from human blood—so that they are treated differently under the law.
For lawyers and compliance teams, the Notification is important because it affects how regulated activities are classified. If a product falls within the exempted categories, the legal consequences under section 13(1) may not apply. Conversely, if a product is not clearly within the exempted list, the default position under the Act may apply, potentially triggering licensing, prohibitions, or other compliance obligations depending on the content of section 13(1).
What Are the Key Provisions?
Section 1 (Citation) is a standard provision that identifies the instrument as the “Human Organ Transplant (Specified Products) Notification 1987.” While it does not create substantive obligations, it is useful for legal citation and for locating the correct instrument in regulatory databases.
Section 2 (Exemption) is the core operative provision. It states that the following products are exempted from the application of section 13(1) of the Act:
(a) Human blood products and plasma fractions
This exemption covers products derived from human blood and specifically includes plasma fractions. In practice, this category is likely to be relevant to blood fractionation products used for therapeutic purposes (for example, certain plasma-derived medicinal products). The legal significance is that such products are not treated as falling within the scope of section 13(1) restrictions, even though they are human-derived.
(b) Human hormones
Human hormones are also exempted. This is particularly relevant to pharmaceutical products and therapeutic hormone preparations. The exemption suggests that the legislature intended to distinguish between organs/tissues intended for transplantation and certain medicinal products that are manufactured and used under separate regulatory regimes (such as pharmaceutical and healthcare product controls).
(c) Vaccines and toxoids
Vaccines and toxoids are exempted. This is an important policy choice because vaccines and toxoids are typically produced for immunisation and public health purposes. By exempting them from section 13(1), the Notification reduces the risk that routine immunisation-related supply chains could be constrained by organ-transplant-specific restrictions.
(d) Diagnostic agents derived from human blood
Finally, the Notification exempts diagnostic agents derived from human blood. Diagnostic agents are used to detect or monitor conditions (for example, laboratory tests). The exemption indicates that diagnostic uses of human blood-derived materials are not intended to be regulated in the same way as transplantation-related activities under section 13(1).
Practical legal effect. The Notification does not repeal or amend the Human Organ Transplant Act. Instead, it operates as a carve-out. The key legal question for practitioners is therefore classification: whether a particular product is within one of the listed categories. If it is, section 13(1) does not apply to that product. If it is not, the exemption will not assist, and the underlying obligations in section 13(1) may be engaged.
Interpretation issues to consider. Even though the extract lists categories, lawyers will often need to interpret terms such as “blood products,” “plasma fractions,” “human hormones,” “vaccines and toxoids,” and “diagnostic agents.” In practice, classification may depend on the product’s composition, manufacturing process, intended use, and regulatory status as a medicinal product or diagnostic. Because the Notification is an exemption from a statutory provision, it may be construed strictly: entities should be prepared to justify why their product falls within the exempted wording.
How Is This Legislation Structured?
This Notification is extremely concise and structured around two provisions:
First, it contains a citation provision (section 1) identifying the instrument.
Second, it contains a single substantive operative provision (section 2) that sets out the exemption list. There are no additional parts, schedules, or detailed procedural requirements in the extract provided. The Notification therefore functions as a straightforward legal instrument: it identifies exempt products and links the exemption to a specific cross-referenced provision in the Human Organ Transplant Act (section 13(1)).
Who Does This Legislation Apply To?
The Notification applies to persons and organisations whose activities would otherwise fall within the scope of section 13(1) of the Human Organ Transplant Act 1987. While the extract does not reproduce section 13(1), the exemption’s design indicates it is relevant to regulated dealings involving human-derived products.
In practical terms, the Notification is likely to be relevant to stakeholders such as:
(i) manufacturers and suppliers of blood-derived medicinal products and plasma fractions;
(ii) pharmaceutical companies producing or distributing hormone preparations;
(iii) vaccine and toxoid manufacturers and distributors;
(iv) diagnostic companies and laboratories dealing with diagnostic agents derived from human blood; and
(v) importers, wholesalers, and healthcare supply chain actors who must determine whether their products are subject to transplant-related restrictions.
However, the exemption is product-specific. Even if an entity’s business is generally within healthcare or biomedical supply, the exemption only helps to the extent the specific product is within one of the listed categories.
Why Is This Legislation Important?
This Notification is important because it clarifies the boundary between organ-transplant regulation and other categories of human-derived medical products. Without such an exemption, section 13(1) could potentially be interpreted to apply broadly to human-derived materials, creating compliance burdens for vaccine, diagnostic, and plasma-derived medicinal product supply chains.
For practitioners, the Notification provides a legally grounded basis to argue that certain products are outside the reach of section 13(1). This can affect licensing requirements, prohibited conduct analysis, and compliance documentation. In regulated industries, even small classification differences can have significant consequences—such as whether a transaction requires specific approvals, whether certain handling or procurement rules apply, and how contractual representations should be drafted.
From an enforcement perspective, the Notification also reduces regulatory ambiguity. It signals legislative intent: the listed products are treated as sufficiently distinct from the types of materials targeted by section 13(1). This supports consistent decision-making by regulators and regulated entities, and it can reduce the risk of inadvertent breaches caused by over-inclusive interpretations.
Finally, the Notification’s amendment history (including the 2025 Revised Edition and earlier amendments) indicates that the legal framework is maintained over time. Practitioners should therefore always verify the current version and confirm that the exemption list has not been modified since the relevant transaction date.
Related Legislation
- Human Organ Transplant Act 1987 (in particular, section 13(1))
- S 694/2022 (amending instrument referenced in the legislative timeline)
Source Documents
This article provides an overview of the Human Organ Transplant (Specified Products) Notification 1987 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.